Piper Sandler analyst David Westenberg lowered the firm’s price target on Myriad Genetics (MYGN) to $14 from $24 and keeps a Neutral rating on ...
The study found that Prequel ® Prenatal Screen with AMPLIFYâ„¢ technology enables reliable results as early as eight-weeks’ gestation. Typically, prenatal cell-free DNA (pcfDNA) screening is offered ...
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 3.75% of ...
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at ...
Research analysts at Leerink Partnrs boosted their FY2024 EPS estimates for Myriad Genetics in a note issued to investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now forecasts that ...
In this article, we are going to take a look at where Myriad Genetics, Inc. (NASDAQ:MYGN) stands against Larry Robbins' other long-term stock picks. Larry Robbins is an American hedge fund manager ...
We recently compiled a list of the Billionaire Larry Robbins’ Long-Term Stock Picks. In this article, we are going to take a ...
Myriad Genetics, Inc. is a molecular diagnostic company, which focuses on developing and marketing of novel predictive and personalized medicines and prognostic medicine tests. It operates through ...
In this article, we are going to take a look at where Myriad Genetics, Inc. (NASDAQ:MYGN) stands against Larry Robbins’ other long-term stock picks. Larry Robbins is an American hedge fund ...